Definium tees up regulatory submission for psychedelic on Phase III hat trick
Definium Therapeutics plans to submit an NDA for LSD-based psychedelic, DT120 in generalised anxiety disorder (GAD) during H1 2027.
Read the full article on the original site.
Read Full Article